Tue Jun 23 2020
suPARnostic® TurbiLatex will now be available for clinical decision making in the Emergency Department of Hospital General Universitario Santa Lucía in Cartagena, Spain.
The hospital will implement suPARnostic® TurbiLatex on its Roche cobas platform to help the process of triage in the emergency department, including also triage in relation to COVID-19 disease.
This is the second hospital in Spain that adopts the suPARnostic® TurbiLatex product in clinical routine use, after the University Hospital in León implemented the product in February 2020.
The Cartagena University Hospital is a 667 bed hospital located in the Murcia Region in the southeast of Spain. The Hospital serves as a reference hospital in the Region and has an uptake population of approx. 300,000 people.
The implementation at the Hospital has been led by Dra. María Dolores Albaladejo Otón (Head of the Clinical Analysis Service) and Dr. Luis García de Guadiana Romualdo (Doctor Specialist in the Clinical Analysis Area).
Jakob Knudsen, CEO of ViroGates, says:”We are happy to see that yet another clinical customer in Spain appreciate how our suPARnostic® TurbiLatex product can add value in the triage process. We have all gone through a difficult time during the first months of the Corona virus outbreak, but the determination of our collaborators at the Hospital, has resulted in a very valuable tool now being available in the triage process. We look forward to a long-term collaboration with the people in the Hospital to support their triage of acute medical patients.”
Dra. María Dolores Albaladejo from Hospital General Universitario Santa Lucía says in a comment:“We are very happy to have this new biomarker that has proven to be a useful tool in the Emergency Department, for making decisions about the need for hospital admission or discharge. We hope that the first results demonstrating its usefulness in patients with COVID 19 can be confirmed soon in our hospital.”